TREM2 and Huntington disease: Specifically, we took advantage of tissue microarrays (TMAs) to assess the expression of these proteins in the striatum37 and then looked at TREM2 and TLR4 genetic variants/single nucleotide polymorphisms (SNPs) as genetic modifiers of disease progression in a large cohort of HD patients (N = 830) obtained from the European Huntington's Disease Network (EHDN).